Geo-Spatial Characteristics of 567 Places of Tick-Borne Encephalitis Infection in Southern Germany, 2018–2020

Tick-borne encephalitis (TBE) is a growing public health problem with increasing incidence and expanding risk areas. Improved prevention requires better understanding of the spatial distribution and ecological determinants of TBE transmission. However, a TBE risk map at sub-district level is still missing for Germany. We investigated the distribution and geo-spatial characteristics of 567 self-reported places of probable TBE infection (POI) from 359 cases notified in 2018–2020 in the study area of Bavaria and Baden-Wuerttemberg, compared to 41 confirmed TBE foci and 1701 random comparator places. We built an ecological niche model to interpolate TBE risk to the entire study area. POI were distributed heterogeneously at sub-district level, as predicted probabilities varied markedly across regions (range 0–93%). POI were spatially associated with abiotic, biotic, and anthropogenic geo-spatial characteristics, including summer precipitation, population density, and annual frost days. The model performed with 69% sensitivity and 63% specificity at an optimised probability threshold (0.28) and an area under the curve of 0.73. We observed high predictive probabilities in small-scale areas, consistent with the known circulation of the TBE virus in spatially restricted microfoci. Supported by further field work, our findings may help identify new TBE foci. Our fine-grained risk map could supplement targeted prevention in risk areas.Peer Reviewe

Evaluation of the COVID-19 vaccination after broad implementation—an interim conclusion for Germany in July 2022

Seit Dezember 2020 stehen in Deutschland Impfstoffe gegen COVID-19 zur Verfügung. Zu den Hauptaufgaben des Fachgebiets Impfprävention des Robert Koch-Instituts (RKI) in der COVID-19-Pandemie gehören die Erhebung von Impfquoten und das Monitoring der Wirksamkeit der Impfung. Der Artikel gibt einen Überblick über die hierfür während der Pandemie etablierten Strukturen, Datengrundlagen und Studien. Ausgehend vom Digitalen Impfquotenmonitoring (DIM), welches für die tagesaktuelle Berechnung der Impfquote in mehreren Altersgruppen verwendet wird, werden die Berechnung der Inzidenzen nach Impfstatus und die Methodik der Impfeffektivitätsschätzung gegen verschiedene Endpunkte (Hospitalisierung, intensivstationäre Betreuung, Tod) beschrieben. Während diese Methode lediglich eine erste Abschätzung der Impfeffektivität erlaubt, kann in bevölkerungsbezogenen nichtrandomisierten Studien eine detailliertere und genauere Untersuchung der Wirksamkeit der COVID-19-Impfstoffe unter Realbedingungen erfolgen. Hierzu wird die gemeinsam mit dem Paul-Ehrlich-Institut (PEI) durchgeführte krankenhausbasierte Fall-Kontrollstudie COViK vorgestellt. Die Vorteile und Limitationen der genannten Strukturen und Instrumente werden diskutiert. Abschließend wird ein Ausblick auf hieraus resultierende künftige Herausforderungen in der Pandemie und beim Übergang in die endemische Lage gegeben.Vaccines against COVID-19 have been available in Germany since December 2020. At the Robert Koch Institute (RKI), the Immunization Unit is responsible for monitoring vaccination coverage and assessment of vaccine effectiveness. This article provides an overview of the respective reporting structures, vaccination databases, and epidemiological studies established by the Immunization Unit during the COVID-19 pandemic. We describe the COVID-19 Digital Vaccination Coverage Monitoring (DIM), which provides daily updates on vaccination coverage by age group. We next describe how, based on the DIM data and COVID-19 case data, the assessment of vaccine effectiveness against different clinical endpoints (hospitalization, intensive care, death) is performed. While this method is used for a preliminary estimate of vaccine efficacy, population-based nonrandomized studies are able to provide more precise and detailed estimates under “real-world” conditions. In this context, we describe the hospital-based case-control study COViK, which is being conducted in collaboration with the Paul Ehrlich Institute (PEI). We discuss strengths and limitations of the abovementioned structures and tools. Finally, we provide an outlook on future challenges that may arise during the ongoing pandemic and during the transition phase into an endemic situation.Peer Reviewe

Geo-Spatial Characteristics of 567 Places of Tick-Borne Encephalitis Infection in Southern Germany, 2018-2020.

Tick-borne encephalitis (TBE) is a growing public health problem with increasing incidence and expanding risk areas. Improved prevention requires better understanding of the spatial distribution and ecological determinants of TBE transmission. However, a TBE risk map at sub-district level is still missing for Germany. We investigated the distribution and geo-spatial characteristics of 567 self-reported places of probable TBE infection (POI) from 359 cases notified in 2018-2020 in the study area of Bavaria and Baden-Wuerttemberg, compared to 41 confirmed TBE foci and 1701 random comparator places. We built an ecological niche model to interpolate TBE risk to the entire study area. POI were distributed heterogeneously at sub-district level, as predicted probabilities varied markedly across regions (range 0-93%). POI were spatially associated with abiotic, biotic, and anthropogenic geo-spatial characteristics, including summer precipitation, population density, and annual frost days. The model performed with 69% sensitivity and 63% specificity at an optimised probability threshold (0.28) and an area under the curve of 0.73. We observed high predictive probabilities in small-scale areas, consistent with the known circulation of the TBE virus in spatially restricted microfoci. Supported by further field work, our findings may help identify new TBE foci. Our fine-grained risk map could supplement targeted prevention in risk areas

Empfehlung und wissenschaftliche Begründung der STIKO zur Indikationserweiterung zur COVID-19-Auffrischimpfung

Die STIKO empfiehlt eine weitere Auffrischimpfung für Personen ab dem Alter von 60 Jahren sowie für Personen im Alter ab 5 Jahren mit erhöhtem Risiko für schwere COVID-19-Verläufe infolge einer Grunderkrankung. Ziel der erweiterten Indikationsstellung ist die Verhinderung von schweren COVID-19-Verläufen und Tod bei besonders gefährdeten Personen. Die Auffrischimpfung soll in der Regel mit einem Mindestabstand von 6 Monaten zur letzten Impfung oder vorherigen SARS-CoV-2-Infektion durchgeführt werden.Peer Reviewe